Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-02-23
2009-12-08
Hobbs, Lisa J (Department: 1657)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S400000, C424S078160, C514S002600
Reexamination Certificate
active
07628985
ABSTRACT:
Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.
REFERENCES:
patent: 4203967 (1980-05-01), Gallo-Torres
patent: 4912120 (1990-03-01), Castelhano et al.
patent: 4929630 (1990-05-01), Castelhano et al.
patent: 5817523 (1998-10-01), Picarelli
patent: 5834428 (1998-11-01), Drucker
patent: 6197356 (2001-03-01), Girsh
patent: 6319726 (2001-11-01), Schuppan et al.
patent: 6410550 (2002-06-01), Coe et al.
patent: 7144569 (2006-12-01), Anderson et al.
patent: 2001/0007690 (2001-07-01), Girsh
patent: 2001/0036639 (2001-11-01), Fine
patent: 2002/0039599 (2002-04-01), Lin et al.
patent: 2002/0076834 (2002-06-01), Detlef et al.
patent: 2003/0215438 (2003-11-01), Hausch et al.
patent: 2003/0224476 (2003-12-01), Chou
patent: 2004/0167069 (2004-08-01), Khosla et al.
patent: 2004/0241664 (2004-12-01), Dekker et al.
patent: 2005/0090653 (2005-04-01), Klaveness et al.
patent: 2005/0244823 (2005-11-01), Drijfhout et al.
patent: 2006/0178299 (2006-08-01), Anderson et al.
patent: 0237082 (1987-09-01), None
patent: 0905518 (1999-03-01), None
patent: WO94/26774 (1994-11-01), None
patent: WO01/25793 (2001-04-01), None
patent: WO03/068170 (2003-08-01), None
Shan et al. (2004) Biochem J. 383: 311-318.
Arentz-Hansen et al. “Celiac Lesion T Cells Recognizes Epitopes that Cluster in Regions of Gliadins Rich in Proline Residues” Gastroenterology, 2002, pp. 803-809, vol. 123, No. 3.
Bethune, et al. “Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease,” Chemistry & Biology, 2006, pp. 637-647, vol. 13.
Castelhano et al., “Synthesis, Chemistry, and Absolute Configuratin of Novel Transglutaminiase Inhibitors Containing a 3-Halo-4,5-dihydroisoxazole” Bioorg. Chem., 1988, pp. 335-340, vol. 16.
Choi et al. “Chemistry and Biology of Dihydroisoxazole Derivatives: Selectives Inhibitors of Human Transglutaminase 2” Chem. & Biol., 2005, pp. 469-475, vol. 12.
de Ritis G. et al. “In Vitro (organ culture) Studies of the Toxicity of Specific A-Gliadin Peptides in celiac Disease” Gastroenbterology, 1988, pp. 41-49, vol. 94.
Freund, K. et al. “Transglutaminase inhibition by 2-[(2-Oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation” Biochemistry, 1994, pp. 10109-10119, vol. 33.
Greenberg, C. et al. “Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues” FASEB J., 1991, pp. 3071-3077, vol. 5.
Hartmann, G. et al. “Rapid degradation of gliadin peptides toxic for coeliac disease patients by proteases from germinating cereals” Journal of Cereal Science, Nov. 2006, pp. 368-371, vol. 44.
Hausch et al. “Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase” Chem Biol., Mar. 2003, pp. 225-231, vol. 10, Issue 3.
Hitomi, K. et al. “GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3),” Biosci. Biotechnol. Biochem., 2000, pp. 657-659, vol. 64, Issue 3.
Kao Castle Pty Ltd Sequence Analysis PCTRIS03104743.
Karpuj et al. “Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine” Nature Med., Feb. 2002, pp. 143-149, vol. 8, Issue 2.
Keillor, J. “Tissue Transglutaminase Inhibition” Chem. & Biol., 2005, pp. 410-412, vol. 12.
Kim et al. “Transglutaminases in disease” Neurochem. Int., 2002, pp. 85-103, vol. 40.
Lorand et al. “Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins” Exp Eye Res., May 1998, pp. 531-536, vol. 66.
Martinet et al. “In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer” Am J Respir Cell Mol Biol., Apr. 2003, pp. 428-435, vol. 28, Issue 4.
Piper et al., “High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac spure”, Biochemistry, Jan. 8, 2002, pp. 386-393, vol. 41, Issue 1.
Piper, J., et al., “Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo,” The Journal of Pharmacology and Experimental Therapeutics, 2004, pp. 213-219, vol. 311, Issue 1.
Sárdy, M. et al. “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis” J. Exp. Med., 2002, pp. 747-757, vol. 195, Issue 6.
Shan, L. et al. “Structural Basis for Gluten Intolerance in Celiac Sprue” Science 2002, pp. 2275-2279, vol. 297.
Shan, L. et al. “Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications of coeliac sprue,” Biochem J, 2004, pp. 311-318, vol. 383.
Sjostrom et al. “Identification of a Gliadin T-Cell Epitope in Coeliac Disease: General Importance of Gliadin Deamidation for Intestinal T-Cell Recognition” Scandinavian Journal of Immunology, Aug. 1998 , pp. 111-115(5), vol. 48, No. 2.
Stepniak, D. et al. “Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease,”Am J Physiol Gastrointest Liver Physiol, 2006, pp. G621-G629, vol. 291.
Vader et al. “The Gluten Response in Children with Celiac Sprue Disease is Directed Toward Multiple Gliadin and Glutenin Peptides” Gastroenterology, 2002, pp. 1729-1737, vol. 122.
Vader et al. “The HLa-DQ2 Gene Dose Effect in Celiac Disease is Doirectly Related to the Magnitude and Breadth of Gluten-Specific T Cell Responses” PNAS, Oct. 14, 2003, pp. 12390-12395, vol. 123, No. 3.
Zhang et al. “Identification of differentially expressed proteins in human glioblastoma cell lines and tumors” Glia., Apr. 15, 2003, pp. 194-208, vol. 42, Issue 2.
Ahnen et al., “Intestinal aminooligopeptidase. In vivo synthesis on intracellular membranes of rat jejunum,” J Biol. Chem., 1982, 257(20):12129-12135.
Arentz-Hansen et al., “Intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase,” J Exp. Med., 2000, 191(4):603-612.
Bordusa et al., “The specificity of prolyl endopeptidase fromFlavobacterium meningoseptum: mapping the S' subsites by positional scanning via acyl transfer,” Bioorg. Med. Chem., 1998, 6(10):1775-1780.
Colot, Genet. Eng. (NY), “The genes encoding wheat storage proteins: towards a molecular understanding of bread-making quality and its genetic manipulation,” 1990, 12:225-241.
Database Derwent, Acc-No. 1996-329479. HIa-Binding Oligopeptide And An Immuno: Regulator Contgit—Used In The Treatment Of Auto: Immune Disease, 1999.
Frazer et al., “Gluten-induced enteropathy: the effect of partially digested gluten,” Lancet, 1959, 2(7097):252-255.
Lahteenoja et al., “Local challenge on oral mucosa with an alpha-gliadin related synthetic peptide in patients with celiac disease,” Am J Gastroenterol., 2000, 95(10):2880-2887.
Lion.Flavobacterium meningosepticum. Genbank Accession #/EMBL #: D10980. Aug. 1, 1992. http://www. infobiogen.fr/srs71bin/cgi-bin/wgetz?-id+4jqa61Mc9PO+[uniprot-ID:PPCE—FLAME]+-e.
Messer et al., “Studies on the mechanism of destruction of the toxic action of wheat gluten in celiac disease by crude papain,” Gut, 1964, 5:295-303.
Messer et al., “Oral papain in gluten intolerance,” Lancet, 1976, 2(7993):1022.
Moodie, Peter, “Traditional Baking Enzymes-Proteases,” Enzyme Development Corporation, 2001, pp. 1-10.
Online-Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 13, 1997.
Schuppan, “Curre
Bethune Michael Thomas
Gass Jonathan David
Khosla Chaitan
Shan Lu
Alvine Pharmaceuticals, Inc.
Bozicevic Field & Francis LLP
Hobbs Lisa J
Sherwood Pamela J.
The Board of Regents of the Leland Stanford Junior University
LandOfFree
Therapeutic enzyme formulations and uses thereof in celiac... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic enzyme formulations and uses thereof in celiac..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic enzyme formulations and uses thereof in celiac... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4120419